NCT01610492View on ClinicalTrials.gov

A Study of Belimumab in Idiopathic Membranous Glomerulonephropathy

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

July 1, 2012

Primary Completion Date

September 24, 2014

Study Completion Date

September 14, 2016

Conditions
Glomerulonephritis, Membranous
Interventions
DRUG

belimumab

10mg/kg administered intravenously

Trial Locations (8)

EX2 5DW

GSK Investigational Site, Exeter

SG1 4AB

GSK Investigational Site, Stevenage

CB2 0QQ

GSK Investigational Site, Cambridge

G11 6NT

GSK Investigational Site, Glasgow

M13 9WL

GSK Investigational Site, Manchester

RG1 5AN

GSK Investigational Site, Reading

M6 8HD

GSK Investigational Site, Salford

E1 1BB

GSK Investigational Site, Whitechapel, London

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01610492 - A Study of Belimumab in Idiopathic Membranous Glomerulonephropathy | Biotech Hunter | Biotech Hunter